Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from C6orf167 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from C6orf167, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 35, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer.

Abstract: The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 43 or immunologically active fragments thereof, which bind to HLA antigen and have cytotoxic T lymphocyte (CTL) inducibility. The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents and compositions of this invention may be used for treating cancer or tumor.

Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from INHBB that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical compositions containing the INHBB polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients.

Abstract: The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.

Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from IQGAP3 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 or HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the IQGAP3 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.

Abstract: A data providing system is provided which includes: a storage section which stores an encoded file obtained by encoding a data file to be distributed with a predetermined common key and an encoded information file obtained by encoding an information data file including information on the common key with a private key different from the common key; and a file transfer section which transfers the encoded file and the encoded information file from the storage section to external electronic device.

Abstract: Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e.

Abstract: An output management system includes a terminal device and an output device, wherein the output management system includes an area management device for managing an access of the user to an area in which the output device is located and a shutoff device for shutting off the access of the user to the area. The area management device has a storing unit for storing registered authentication data, an inputting unit for inputting input authenticated data, a checking unit for checking the input authenticated data and the registered authentication data, and a shutoff releasing unit for releasing the shutoff by the shutoff device when the input authenticated data and the registered authentication data conform to each other.

Abstract: Provided is an image forming system, including an image forming apparatus connected to a communication network and a server connected to the communication network. The image forming apparatus includes a management service processing unit that transmits a registration request for registering the image forming apparatus as a target of a management service to the server. The server includes a data management unit that receives the registration request and registers the image forming apparatus that has transmitted the registration request as the target of the management service. The management service processing unit periodically collects device information including a state and/or a setting of the image forming apparatus and transmits the device information to the data management unit. The data management unit periodically acquires the device information from the management service processing unit and retains the device information.

Abstract: An image forming apparatus includes an application management unit that detects a restricted function of which use by a given user is inhibited from among functions within an application. The image forming apparatus further includes a function monitoring unit that registers the restricted function detected by the application management unit, and inhibits the user from executing the restricted function.

Abstract: An image forming apparatus comprises a communication interface unit that performs communication with a terminal device, a storage unit that stores an application program installed under license and a management application program for managing the application program, an arithmetic processing unit that executes the application program and the management application program stored in the storage unit, a determination unit that determines whether or not predetermined software installed in the terminal device has a legitimate license code corresponding to the license of the management application program, and an installing unit that, when it is determined that the predetermined software has a legitimate license code, obtains the application program from the terminal device and installs the application program into the storage unit.

Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.

Abstract: The present invention teaches and claims an electronic appliance for controlling a device via a controller comprises an application managing unit, a storing unit, a controller API and a secondary API. The application managing unit manages an application. The application is prepared with the use of an API, which operates the device to offer a service to a user, and is selected upon activation of the electronic appliance. The storing unit stores information about a correlation between the application and the API. The controller API is called by the application, and issues a request to the controller such that the controller operates the device. The secondary API has an interface so as not to be implemented in the controller API, and is called by the application on the basis of any correlation information, which consequently starts up the application with the use of the interface when version information of the API is newer than version information of the controller API.

Abstract: The present invention claims and discloses an electronic device comprising a storage part for storing a license check processing program for checking a license in order to execute a processing function of an application program, license setting information containing location information where the license check processing program is executed within the application program; and an application program execution part for executing the application program by associating the license check processing program with a location preset in the application program based on the license setting information stored in the storage part. The present invention further teaches performing a license check processing by the license check processing program associated with the location, and when the license is not properly authenticated, the program in accordance with the present invention will skip the processing function corresponding to the license check processing program to execute a subsequent processing function.

Abstract: A data providing system is provided which includes: a storage section which stores an encoded file obtained by encoding a data file to be distributed with a predetermined common key and an encoded information file obtained by encoding an information data file including information on the common key with a private key different from the common key; and a file transfer section which transfers the encoded file and the encoded information file from the storage section to external electronic device.

Abstract: An input apparatus and an input control method are provided that enable the confirmation of an operation state using speech each time an operation key is depressed and enable the execution of distributed functions using a straightforward operation. A plurality of functions is allocated to a numeric keypad, and audio is outputted for the operation state by way of the numeric keypad from an audio output section every time an operation function changes. A function just previous to operation of the numeric keypad can, therefore, be decided by using a setting key, and control may be carried out by a control unit.

Abstract: The present invention provides the output management system in which the security is effectively improved by access control to the area, capable of efficiently performing the output processing or picking up the output matter, and capable of utilizing the output device lacking the security function without modification.